Trial intelligence / Profile preview

ARA 290 for diabetic macular oedema

2015-001940-12Phase 2Terminated

Sponsor
Belfast Health and Social Care Trust
Start
Sep 2015
Modality
Recombinant Proteins and Enzymes, Peptides
Countries
1
01

Overview

Phase 2, single-arm trial of cibinetide in diabetic macular edema (DME), sponsored by Belfast Health and Social Care Trust. Primary endpoint: Change in best corrected distance visual acuity. Started Sep 2015; status: terminated.

02

Drugs

cibinetide
03

Conditions

diabetic macular edema (DME)

Beyond the preview

Go deeper on 2015-001940-12.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2015-001940-12.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call